Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· July 8, 2026

UPDATE: Endogenex Announces Full Enrollment of the ReCET Clinical Study

View original at globenewswire.com

UPDATE: Endogenex Announces Full Enrollment of the ReCET Clinical Study MINNEAPOLIS, July 08, 2026 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), announced that the ReCET Clinical Study has reached full enrollment…

Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Completing enrollment reflects the significant unmet need in type 2 diabetes and growing recognition that treatment approaches beyond pharmacotherapy can offer real value; the duodenum's role in metabolic regulation is well established and REGENT-1 feasibility data provided a strong scientific basis for the ReCET trial, which can now test the hypothesis at scale in a blinded, controlled design.
60% confidence
Maintaining adequate blood glucose control remains a substantial challenge for many T2D patients despite multiple medications; full enrollment is an important step toward determining whether targeted restoration of duodenal function can produce durable, clinically meaningful improvements in glycemic control.
60% confidence
Reaching full enrollment is a defining moment for Endogenex and patients with type 2 diabetes; even with GLP-1 receptor agonists and SGLT2 inhibitors, the disease often progresses because the gut has gone untreated, and with 350 patients enrolled across two countries the company is focused on generating randomized evidence to bring the therapy to patients.
60% confidence